Literature DB >> 25700984

Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 gene.

John T Isaacs1.   

Abstract

This commentary highlights the article by Ge et al, which proposes the use of methylation and expression of SRD5A2 as a gene signature to tailor therapies for prostatic diseases.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25700984      PMCID： PMC4348462          DOI： 10.1016/j.ajpath.2015.01.001

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


  25 in total

1.  Apoptotic versus proliferative activities in human benign prostatic hyperplasia.

Authors:  N Kyprianou; H Tu; S C Jacobs
Journal:  Hum Pathol       Date:  1996-07       Impact factor: 3.466

2.  Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.

Authors:  Yi Xu; Susan L Dalrymple; Robyn E Becker; Samuel R Denmeade; John T Isaacs
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

Review 3.  Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?

Authors:  Simon A Williams; Pratap Singh; John T Isaacs; Samuel R Denmeade
Journal:  Prostate       Date:  2007-02-15       Impact factor: 4.104

Review 4.  Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?

Authors:  Gero Kramer; Dieter Mitteregger; Michael Marberger
Journal:  Eur Urol       Date:  2006-12-11       Impact factor: 20.096

5.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Authors:  J D McConnell; R Bruskewitz; P Walsh; G Andriole; M Lieber; H L Holtgrewe; P Albertsen; C G Roehrborn; J C Nickel; D Z Wang; A M Taylor; J Waldstreicher
Journal:  N Engl J Med       Date:  1998-02-26       Impact factor: 91.245

6.  DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate.

Authors:  Rongbin Ge; Zongwei Wang; Seth K Bechis; Alexander G Otsetov; Shengyu Hua; Shulin Wu; Chin-Lee Wu; Shahin Tabatabaei; Aria F Olumi
Journal:  Am J Pathol       Date:  2015-02-17       Impact factor: 4.307

Review 7.  The role of inflammation in prostate cancer.

Authors:  Karen S Sfanos; Heidi A Hempel; Angelo M De Marzo
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

8.  Alpha-blockade downregulates myosin heavy chain gene expression in human benign prostatic hyperplasia.

Authors:  V K Lin; E A Benaim; J D McConnell
Journal:  Urology       Date:  2001-01       Impact factor: 2.649

9.  Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.

Authors:  Bora Gurel; M Scott Lucia; Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; Alan R Kristal; Howard L Parnes; Ashraful Hoque; Scott M Lippman; Siobhan Sutcliffe; Sarah B Peskoe; Charles G Drake; William G Nelson; Angelo M De Marzo; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-18       Impact factor: 4.254

Review 10.  Evolution of steroid-5alpha-reductases and comparison of their function with 5beta-reductase.

Authors:  Valérie S Langlois; Dapeng Zhang; Gerard M Cooke; Vance L Trudeau
Journal:  Gen Comp Endocrinol       Date:  2009-08-15       Impact factor: 2.822
View more
  1 in total

1.  Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors.

Authors:  Daniel Taussky; Julie Piotte; Kevin C Zorn; Marc Zanaty; Vimal Krishnan; Carole Lambert; Jean-Paul Bahary; Marie-Claude Beauchemin; Maroie Barkati; Cynthia Ménard; Guila Delouya
Journal:  Strahlenther Onkol       Date:  2017-07-10       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.